Literature DB >> 9215736

A simple and reliable method for screening retroviral producer clones without selectable markers.

M Onodera1, A Yachie, D M Nelson, H Welchlin, R A Morgan, R M Blaese.   

Abstract

Simplified retroviral vectors that lack dominant selectable markers are being used with increasing frequency. These simplified vectors may offer a number of advantages over selectable marker-containing constructs, including potentially higher titers and less immunogenicity. However, the use of these vectors has been limited by the cumbersome experimental approaches in establishing and characterizing useful producer cell clones. To address this issue, a simple and reliable assay was developed to identify retroviral producer cell lines with or without dominant selectable markers. Producer cells were first generated by standard transfection/transduction and clones isolated by limiting dilution. Supernatant from each clone was then screened by RNA dot blot to identify the best producer clone candidates. The semiquantitative nature of the RNA dot blot assay was validated using a retroviral vector containing neomycin phosphotransferase (neo). Titers obtained by conventional G418-resistant colony forming units/ml (G418(R) cfu/ml) assays strongly correlated with the values by RNA dot blot procedure. RNA dot blot results also correlated well with titers estimated by Southern analysis of HeLa cells transduced with supernatant from each clone. The RNA dot blot technique is a rapid (2 days) and reliable method to screen retroviral producer cells, thereby facilitating the generation and characterization of simplified retroviral producer cell clones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9215736     DOI: 10.1089/hum.1997.8.10-1189

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  20 in total

1.  Development of murine leukemia virus-based self-activating vectors that efficiently delete the selectable drug resistance gene during reverse transcription.

Authors:  K A Delviks; V K Pathak
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  High-throughput selection of retrovirus producer cell lines leads to markedly improved efficiency of germ line-transmissible insertions in zebra fish.

Authors:  Wenbiao Chen; Shawn Burgess; Greg Golling; Adam Amsterdam; Nancy Hopkins
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

Authors:  Steven A Feldman; Stephanie L Goff; Hui Xu; Mary A Black; James N Kochenderfer; Laura A Johnson; James C Yang; Qiong Wang; Maria R Parkhurst; Scott Cross; Richard A Morgan; Kenneth Cornetta; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2010-12-12       Impact factor: 5.695

4.  Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Authors:  Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

6.  Splicing mediates the activity of four putative cellular internal ribosome entry sites.

Authors:  Brian T Baranick; Nathan A Lemp; Jill Nagashima; Kei Hiraoka; Noriyuki Kasahara; Christopher R Logg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-07       Impact factor: 11.205

7.  Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.

Authors:  Jennifer A Wargo; Paul F Robbins; Yong Li; Yangbing Zhao; Mona El-Gamil; Diana Caragacianu; Zhili Zheng; Julie A Hong; Stephanie Downey; David S Schrump; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2008-08-02       Impact factor: 6.968

8.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

9.  Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.

Authors:  Steven A Feldman; Hui Xu; Mary A Black; Tristen S Park; Paul F Robbins; James N Kochenderfer; Richard A Morgan; Steven A Rosenberg
Journal:  Hum Gene Ther Methods       Date:  2014-08       Impact factor: 2.396

10.  Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.

Authors:  Cary Hsu; John D Abad; Richard A Morgan
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.